Dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer

Document first published:: 6 March 2020
Page updated:: 6 March 2020
Topic:: Specialised commissioning
Publication type:: Policy or strategy, Report

NHS England will commission dexrazoxane for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer in accordance with the criteria outlined in this document.